Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DAA + Immunotherapy in HCC with HCV
NCT05717400Phase 4Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Mar 2023
- Primary completion
- Aug 2024
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of sofosbuvir, velpatasvir and voxilaprevir in hepatocellular carcinoma (HCC) and chronic hepatitis C (CHC), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Overall Response Rate at 9 months, Sustained Virologic Response at 9 months and 1 more. Started Mar 2023; status: terminated.
02
Drugs
sofosbuvirvelpatasvirvoxilaprevir
03
Conditions
hepatocellular carcinoma (HCC)chronic hepatitis C (CHC)
Beyond the preview
Go deeper on NCT05717400.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05717400.